Login
Home
Charts
Search
Watchlist
Products

Heranba Industries Ltd

HERANBA·NSE
166.47-0.37%Tue, 22 Sept '26

Heranba Industries Ltd

HERANBA
NSE
166.47
-0.37%
|Tue, 22 Sept '26
SOICxStockScans Reports
6M
Price
Charts
Documents

Quick Ratios

Edit Ratios
Mkt Cap
Market Capitalization
666Cr
Close
Close Price
166.47
Industry
Industry
Pesticides/Agrochemicals
PE
Price To Earnings
PS
Price To Sales
0.44
Revenue
Revenue
1,526Cr
Rev Gr TTM
Revenue Growth TTM
-2.56%
PAT Gr TTM
PAT Growth TTM
-853.72%

Quarterly Results

Consolidated
Standalone
Numbers
Percentage
QuarterSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue
RevenueCr
424300258296437341335452522301319383
Growth YoY
Revenue Growth YoY%
0.98.6-0.97.73.113.929.852.719.3-11.7-4.6-15.3
Expenses
ExpensesCr
380275246256378329349421473289343334
Operating Profit
Operating ProfitCr
442412406013-14314912-2349
OPM
OPM%
10.48.14.813.613.63.7-4.36.99.44.1-7.312.8
Other Income
Other IncomeCr
225130313-34-66
Interest Expense
Interest ExpenseCr
235566141212121413
Depreciation
DepreciationCr
668131414162126262522
PBT
PBTCr
381742443-7-41118-22-6820
Tax
TaxCr
113475315102-1013
PAT
PATCr
2714-11738-10-426-2-23-587
Growth YoY
PAT Growth YoY%
-42.910.1-106.5396.340.0-174.5-5,608.2-62.0-105.7-126.0-40.011.2
NPM
NPM%
6.34.7-0.35.68.6-3.0-12.41.4-0.4-7.8-18.31.8
EPS
EPS
6.73.5-0.14.29.5-2.5-10.41.50.4-5.8-14.41.8
QuarterSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue
RevenueCr
424300258296437341335452522301319383
Growth YoY
Revenue Growth YoY%
0.98.6-0.97.73.113.929.852.719.3-11.7-4.6-15.3
Expenses
ExpensesCr
380275246256378329349421473289343334
Operating Profit
Operating ProfitCr
442412406013-14314912-2349
OPM
OPM%
10.48.14.813.613.63.7-4.36.99.44.1-7.312.8
Other Income
Other IncomeCr
225130313-34-66
Interest Expense
Interest ExpenseCr
235566141212121413
Depreciation
DepreciationCr
668131414162126262522
PBT
PBTCr
381742443-7-41118-22-6820
Tax
TaxCr
113475315102-1013
PAT
PATCr
2714-11738-10-426-2-23-587
Growth YoY
PAT Growth YoY%
-42.910.1-106.5396.340.0-174.5-5,608.2-62.0-105.7-126.0-40.011.2
NPM
NPM%
6.34.7-0.35.68.6-3.0-12.41.4-0.4-7.8-18.31.8
EPS
EPS
6.73.5-0.14.29.5-2.5-10.41.50.4-5.8-14.41.8

Profit & Loss

Consolidated
Standalone
Numbers
Percentage
Financial YearMar 2023Mar 2024Mar 2025Mar 2026TTM
Revenue
RevenueCr
1,3191,2571,4101,5951,526
Growth
Revenue Growth%
-4.712.113.1-2.6
Expenses
ExpensesCr
1,1631,1801,3121,5261,439
Operating Profit
Operating ProfitCr
15677986987
OPM
OPM%
11.86.17.04.35.7
Other Income
Other IncomeCr
1214881
Interest Expense
Interest ExpenseCr
812315051
Depreciation
DepreciationCr
2326579899
PBT
PBTCr
1385218-71-62
Tax
TaxCr
331816715
PAT
PATCr
104352-78-77
Growth
PAT Growth%
-66.9-93.5-3,547.1-853.7
NPM
NPM%
7.92.70.2-4.9-5.0
EPS
EPS
26.18.70.8-19.1-18.1
Financial YearMar 2023Mar 2024Mar 2025Mar 2026TTM
Revenue
RevenueCr
1,3191,2571,4101,5951,526
Growth
Revenue Growth%
-4.712.113.1-2.6
Expenses
ExpensesCr
1,1631,1801,3121,5261,439
Operating Profit
Operating ProfitCr
15677986987
OPM
OPM%
11.86.17.04.35.7
Other Income
Other IncomeCr
1214881
Interest Expense
Interest ExpenseCr
812315051
Depreciation
DepreciationCr
2326579899
PBT
PBTCr
1385218-71-62
Tax
TaxCr
331816715
PAT
PATCr
104352-78-77
Growth
PAT Growth%
-66.9-93.5-3,547.1-853.7
NPM
NPM%
7.92.70.2-4.9-5.0
EPS
EPS
26.18.70.8-19.1-18.1

Balance Sheet

Consolidated
Standalone
Numbers
Percentage
Financial YearMar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
Equity CapitalCr
40404040
Reserves
ReservesCr
770803801722
Current Liabilities
Current LiabilitiesCr
3395918601,107
Non Current Liabilities
Non Current LiabilitiesCr
133610394
Total Liabilities
Total LiabilitiesCr
1,1621,4801,8131,970
Current Assets
Current AssetsCr
8448401,0331,199
Non Current Assets
Non Current AssetsCr
318639780771
Total Assets
Total AssetsCr
1,1621,4801,8131,970
Financial YearMar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
Equity CapitalCr
40404040
Reserves
ReservesCr
770803801722
Current Liabilities
Current LiabilitiesCr
3395918601,107
Non Current Liabilities
Non Current LiabilitiesCr
133610394
Total Liabilities
Total LiabilitiesCr
1,1621,4801,8131,970
Current Assets
Current AssetsCr
8448401,0331,199
Non Current Assets
Non Current AssetsCr
318639780771
Total Assets
Total AssetsCr
1,1621,4801,8131,970

Cash Flow

Consolidated
Standalone
Financial YearMar 2024Mar 2025Mar 2026
Operating Cash Flow
Operating Cash FlowCr
107101-96
Investing Cash Flow
Investing Cash FlowCr
-241-239-89
Financing Cash Flow
Financing Cash FlowCr
62152166
Net Cash Flow
Net Cash FlowCr
-7214-19
Free Cash Flow
Free Cash FlowCr
-145-137-188
CFO To PAT
CFO To PAT%
310.74,502.2123.7
CFO To EBITDA
CFO To EBITDA%
139.5103.5-138.6
Financial YearMar 2024Mar 2025Mar 2026
Operating Cash Flow
Operating Cash FlowCr
107101-96
Investing Cash Flow
Investing Cash FlowCr
-241-239-89
Financing Cash Flow
Financing Cash FlowCr
62152166
Net Cash Flow
Net Cash FlowCr
-7214-19
Free Cash Flow
Free Cash FlowCr
-145-137-188
CFO To PAT
CFO To PAT%
310.74,502.2123.7
CFO To EBITDA
CFO To EBITDA%
139.5103.5-138.6

Ratios

Consolidated
Standalone
Financial YearMar 2023Mar 2024Mar 2025Mar 2026Current
Valuation Ratios
Valuation Ratios
Market Cap
Market CapitalizationCr
1,1181,134852629666
Price To Earnings
Price To Earnings
10.732.5276.4
Price To Sales
Price To Sales
0.80.90.60.40.4
Price To Book
Price To Book
1.41.41.00.80.9
EV To EBITDA
EV To EBITDA
7.016.411.716.913.9
Profitability Ratios
Profitability Ratios
GPM
GPM%
22.419.821.418.718.7
OPM
OPM%
11.86.17.04.35.7
NPM
NPM%
7.92.70.2-4.9-5.0
ROCE
ROCE%
16.16.44.1-1.6-1.6
ROE
ROE%
12.94.10.3-10.2-10.2
ROA
ROA%
9.02.30.1-3.9-3.9
Operational Ratios
Operational Ratios
Solvency Ratios
Solvency Ratios
Liquidity Ratios
Liquidity Ratios
Financial YearMar 2023Mar 2024Mar 2025Mar 2026Current
Valuation Ratios
Valuation Ratios
Market Cap
Market CapitalizationCr
1,1181,134852629666
Price To Earnings
Price To Earnings
10.732.5276.4
Price To Sales
Price To Sales
0.80.90.60.40.4
Price To Book
Price To Book
1.41.41.00.80.9
EV To EBITDA
EV To EBITDA
7.016.411.716.913.9
Profitability Ratios
Profitability Ratios
GPM
GPM%
22.419.821.418.718.7
OPM
OPM%
11.86.17.04.35.7
NPM
NPM%
7.92.70.2-4.9-5.0
ROCE
ROCE%
16.16.44.1-1.6-1.6
ROE
ROE%
12.94.10.3-10.2-10.2
ROA
ROA%
9.02.30.1-3.9-3.9
Operational Ratios
Operational Ratios
Solvency Ratios
Solvency Ratios
Liquidity Ratios
Liquidity Ratios
Heranba Industries is a crop-protection company built from a single chemical building block - it started in 1996 making one intermediate for synthetic pyrethroid insecticides, then spent three decades stepping forward into active ingredients, finished formulations, and eventually its own branded products sold through 10,000 village-level dealers. The founders, two first-generation technocrat brothers who bought the company in 1994, turned a small Vapi unit into one of India’s largest domestic pyrethroid producers, now present in over 75 countries. The recurring approach is vertical integration: make the intermediate, consume it to make the technical, formulate it into a finished spray or powder, and increasingly sell it under a proprietary brand - capturing margin at every step rather than handing it to someone else. # Business segments A single integrated engine - crop-protection chemicals built on synthetic pyrethroid chemistry - that spans four commercial verticals and the entire value chain from raw intermediates to branded farm-gate products. ## 1. Crop-protection chemicals: from a single intermediate to the farmer’s shelf **Heranba makes the starting chemical, the active ingredient, and the finished product under one roof - then sells that output through four distinct channels, each with different customers and economics.** - **The value chain starts with intermediates** - the foundational molecule is Cypermethric Acid Chloride (CMAC), first produced in 1996, and the company now makes a family of related intermediates including High CIS CMAC, Bromobenzenes, Metaphenoxy Benzaldehyde (MPBD), and NPBR, most of which are consumed captively to make the next stage rather than sold externally. - **Technicals are the bulk active ingredients** - these are the concentrated insect-killing, fungus-killing, or weed-killing compounds sold in large volumes to other formulators; the portfolio spans insecticides (Cypermethrin, Deltamethrin, Lambda Cyhalothrin, Permethrin and others), fungicides (Dodine, Hexaconazole, Tebuconazole), herbicides (Pendimethalin, Glyphosate, Metribuzin), and a plant growth regulator, with the company already handling five of the ten-to-fourteen pyrethroid molecules in existence. - **Formulations are the ready-to-use products farmers buy** - technicals are mixed with adjuvants into over a dozen physical forms (emulsifiable concentrates, capsule suspensions, wettable powders, water-dispersible granules and more), sold under proprietary brands like PROGRESS PLUS, HAURIS, and HERACLAIM-XP, with more than 400 products commercialised to date. - **Four commercial verticals split the customer base** - Technicals (Domestic) supplies Indian agrochemical companies; Technicals (Exports) ships active ingredients to formulators worldwide; Formulations (Branded) sells own-label products through a network of over 10,000 dealers across 20 states; and Formulations (Exports) manufactures finished products tailored for overseas buyers. - **The mix has tilted decisively toward formulations** - three years ago technicals were roughly 70% of sales; by FY25 branded formulations alone contributed 48% of revenue and formulation exports another 8%, meaning more than half the top line now comes from finished products rather than bulk actives, which improves margins because captive technicals capture the value-add at the formulation stage. ## 2. Manufacturing and backward integration: seven plants that keep more steps in-house **The company has expanded from four factories to seven in three years, adding capacity that both increases scale and pulls more of the chemical chain under its own control.** - **Seven facilities across two states** - Units I, II, and IV are in Vapi, Gujarat, making technicals, CMAC isomers, and bromine derivatives; Unit III in Sarigam is the formulations and packing hub with a rooftop solar plant; the Sarigam expansion (via subsidiary HOPL) added two phases of technical capacity totalling 18,600 MTPA; the Saykha greenfield unit adds 6,000 MTPA of herbicide and intermediate capacity with hydrogenation and nitration capability; and the Tarapur unit in Maharashtra, acquired through the Daikaffil purchase, makes optical brightening agents and textile chemicals. - **Aggregate capacity has roughly doubled** - technicals and intermediates capacity rose from 12,900 MTPA in FY24 to 26,700 MTPA in FY25, while formulations capacity moved from 25,000 to 30,000 MTPA, supported by 384 reactors across all sites. - **Backward integration lowers the reliance on outsiders** - Unit IV was built specifically to recover bromine in-house rather than sending it to external job workers, and the company sources most raw materials indigenously, primarily from within Gujarat, with minimal imports. - **The Daikaffil acquisition opens a new path** - the Tarapur site is being converted into a world-class R&D centre with a 15-reactor pilot plant and 60 scientists in the first phase, laying the foundation for a Contract Research and Manufacturing Services (CRAMS) business that would serve agrochemical, pharmaceutical, and specialty-chemical clients. # Research and development **Three DSIR-recognised labs with 48 scientists do the work that feeds the registration pipeline and keeps the product shelf fresh - process chemistry, new formulations, and the data packages regulators demand.** - **R&D is the engine behind new product registrations** - the team developed five herbicides, four fungicides, and three insecticides in FY25 alone, feeding a cumulative registration count that has grown from 400 in 49 countries in FY22 to 1,084 across 54 countries in FY25, with another 183 in the pipeline. - **The labs are equipped for export-grade analytical work** - the analytical lab holds NABL accreditation under ISO/IEC 17025:2017, and instruments like HPLC, GC, and electron microscopes allow the identification and quantification of impurities down to the levels required by regulated markets such as Europe and the United States. - **A formulation-development pilot plant mimics commercial production** - equipment including a bead mill, air jet mill, extruders, and fluidised bed dryer lets the team test new formulation types at small scale before scaling up to the main factories. - **The planned Daikaffil centre will double the scientific workforce** - the Tarapur R&D hub will add 60 scientists focused on synthetic chemistry, analytical research, formulation development, and pilot-plant operations, supporting the CRAMS entry and expanding the molecule pipeline. # Group structure and partners **A family-run listed company with two operating subsidiaries that house the new manufacturing capacity and the acquired Daikaffil business, plus a web of overseas entities in early stages.** - **Promoter family holds the reins** - brothers Sadashiv K. Shetty (Chairman) and Raghuram K. Shetty (Managing Director) founded the business, and their sons Raunak and Shriraj are now Whole-Time Directors, creating a second-generation succession with the board split evenly between executive and non-executive directors. - **Heranba Organics Pvt Ltd (HOPL) is the manufacturing subsidiary** - incorporated in August 2022, it operates the Sarigam and Saykha plants; in April 2026 the parent converted ₹45 Crores of inter-corporate deposits into optionally fully convertible debentures while retaining 100% equity control. - **Overseas entities are in formation** - the company has announced plans for a Taiwan subsidiary and a China joint venture in the agrochemical space, though these remain at the approval or discussion stage.

Documents — Heranba Industries Ltd

  • Q3 FY2025 Earnings Call Transcript (Dec 2024, PDF): https://www.stockscans.in/document/n5sphbzlfdtnv3k1w8rei6j1.pdf
  • Q2 FY2025 Earnings Call Transcript (Sep 2024, PDF): https://www.stockscans.in/document/5n8zy7f44boy8tqu065us8fa.pdf
  • Q3 FY2023 Earnings Call Transcript (Dec 2022, PDF): https://www.stockscans.in/document/fhj4a8et6wnvg44ttt12fm8q.pdf
  • Q2 FY2023 Earnings Call Transcript (Sep 2022, PDF): https://www.stockscans.in/document/4uy949hk8wrievlwnqxkydfp.pdf
  • Q1 FY2023 Earnings Call Transcript (Jun 2022, PDF): https://www.stockscans.in/document/86j8ti7hi7vecrz0d6hqkqnm.pdf
  • Q4 FY2022 Earnings Call Transcript (Mar 2022, PDF): https://www.stockscans.in/document/grwz9eqhlh7fdto0iwn1ivr4.pdf
  • Q2 FY2022 Earnings Call Transcript (Sep 2021, PDF): https://www.stockscans.in/document/ondotl4zdgzdkqoggkxofob7.pdf
  • Q1 FY2022 Earnings Call Transcript (Jun 2021, PDF): https://www.stockscans.in/document/orj57vjwp2rcrjlosfv0szyf.pdf
  • Q1 FY2027 Quarterly Result (Jun 2026, PDF): https://www.stockscans.in/document/k7vb8e80xvudcqvu8ziegyai.pdf
  • Q4 FY2026 Quarterly Result (Mar 2026, PDF): https://www.stockscans.in/document/0b0bosgvem5gn9kdended7i7.pdf
  • Q3 FY2026 Quarterly Result (Dec 2025, PDF): https://www.stockscans.in/document/ronl23jm0rl1g1wquzeabs15.pdf
  • Q2 FY2026 Quarterly Result (Sep 2025, PDF): https://www.stockscans.in/document/lumtqmxrym4hsi9q38ime6mr.pdf
  • Q1 FY2026 Quarterly Result (Jun 2025, PDF): https://www.stockscans.in/document/i6e1wv89nzj5s61jlyi5zja4.pdf
  • Q4 FY2025 Quarterly Result (Mar 2025, PDF): https://www.stockscans.in/document/o2e1o039os8ed3g3j6pz4kgg.pdf
  • Q3 FY2025 Quarterly Result (Dec 2024, PDF): https://www.stockscans.in/document/gst7yox1u40zjaobx12judan.pdf
  • Q2 FY2025 Quarterly Result (Sep 2024, PDF): https://www.stockscans.in/document/awij4ocddcsz8tyz5tzlm5ns.pdf
  • Q2 FY2025 Investor Presentation (Sep 2024, PDF): https://www.stockscans.in/document/u0j1qpxw7zex823ll34kv323.pdf
  • Q1 FY2025 Investor Presentation (Jun 2024, PDF): https://www.stockscans.in/document/4dnd4q4m97hkfnuz91e01n6e.pdf
  • Q4 FY2024 Investor Presentation (Mar 2024, PDF): https://www.stockscans.in/document/1vifecav5txat3jsah7bmzg1.pdf
  • Q3 FY2024 Investor Presentation (Dec 2023, PDF): https://www.stockscans.in/document/xjp2karnaz8ce432akq2em06.pdf
  • Q2 FY2024 Investor Presentation (Sep 2023, PDF): https://www.stockscans.in/document/iruoqx130c1gvfdrmthpx6fz.pdf
  • Q1 FY2024 Investor Presentation (Jun 2023, PDF): https://www.stockscans.in/document/fw1k719qglnwz8esnxtjv3av.pdf
  • Q4 FY2023 Investor Presentation (Mar 2023, PDF): https://www.stockscans.in/document/m27jwz0wjavtrqkvzvr5n7mt.pdf
  • Q3 FY2023 Investor Presentation (Dec 2022, PDF): https://www.stockscans.in/document/1fc2hwt5cc8cmr65zmniueu7.pdf
  • FY2026 Annual Report (PDF): https://www.stockscans.in/document/0331h650uum00kp6s7xe0rlk.pdf
  • FY2025 Annual Report (PDF): https://www.stockscans.in/document/7yf1wacosi0fdebpnt6r2nwc.pdf
  • FY2024 Annual Report (PDF): https://www.stockscans.in/document/nuev7h0zgxong4n0q5opskan.pdf
  • FY2023 Annual Report (PDF): https://www.stockscans.in/document/1rrvp8efhbgxo5selfw3j65m.pdf
  • FY2022 Annual Report (PDF): https://www.stockscans.in/document/mqus6khmwe62bq04mvuluae1.pdf
  • FY2021 Annual Report (PDF): https://www.stockscans.in/document/p9628iw6wvs6egcsooal3n0i.pdf

Concall Transcript Summaries — Heranba Industries Ltd

  • Q3 FY2025 Concall Transcript Summary (Dec 2024): https://www.stockscans.in/company/NSE%3AHERANBA/transcript-notes/202412/n5sphbzlfdtnv3k1w8rei6j1.pdf
  • Q2 FY2025 Concall Transcript Summary (Sep 2024): https://www.stockscans.in/company/NSE%3AHERANBA/transcript-notes/202409/5n8zy7f44boy8tqu065us8fa.pdf
  • Q3 FY2023 Concall Transcript Summary (Dec 2022): https://www.stockscans.in/company/NSE%3AHERANBA/transcript-notes/202212/fhj4a8et6wnvg44ttt12fm8q.pdf
  • Q2 FY2023 Concall Transcript Summary (Sep 2022): https://www.stockscans.in/company/NSE%3AHERANBA/transcript-notes/202209/4uy949hk8wrievlwnqxkydfp.pdf
  • Q1 FY2023 Concall Transcript Summary (Jun 2022): https://www.stockscans.in/company/NSE%3AHERANBA/transcript-notes/202206/86j8ti7hi7vecrz0d6hqkqnm.pdf